Purpose: To describe the patient's allergic response to anti-vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization.
Methods: Clinical case report.
Results: Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept.
Conclusion: Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICB.0000000000000581 | DOI Listing |
Publication Analysis
Top Keywords
bevacizumab ranibizumab
12
anti-vascular endothelial
8
endothelial growth
8
growth factor
8
allergic reaction
4
reaction intravitreal
4
intravitreal administration
4
administration anti-vascular
4
factor agents
4
agents purpose
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!